Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Cash & Current Investments (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Cash & Current Investments for 12 consecutive years, with $140.1 million as the latest value for Q1 2026.

  • For Q1 2026, Cash & Current Investments fell 11.41% year-over-year to $140.1 million; the TTM value through Mar 2026 reached $140.1 million, down 11.41%, while the annual FY2025 figure was $154.5 million, 5.83% down from the prior year.
  • Cash & Current Investments hit $140.1 million in Q1 2026 for Syndax Pharmaceuticals, down from $154.5 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $570.7 million in Q4 2023 and bottomed at $63.3 million in Q1 2023.
  • Average Cash & Current Investments over 5 years is $234.6 million, with a median of $154.5 million recorded in 2025.
  • On a YoY basis, Cash & Current Investments climbed as much as 666.34% in 2023 and fell as far as 84.09% in 2023.
  • Syndax Pharmaceuticals' Cash & Current Investments stood at $74.5 million in 2022, then skyrocketed by 666.34% to $570.7 million in 2023, then plummeted by 71.24% to $164.1 million in 2024, then fell by 5.83% to $154.5 million in 2025, then dropped by 9.37% to $140.1 million in 2026.
  • According to Business Quant data, Cash & Current Investments over the past three periods came in at $140.1 million, $154.5 million, and $135.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.